Incannex Healthcare IXHL
NASDAQ IXHL
$2.76 +0.01 (+0.53%)
At close: Oct 21, 2026 · 4:00 PM EDT

Incannex Healthcare (IXHL) EBITDA Margin (2024)

Updated

Incannex Healthcare (IXHL) reported EBITDA Margin of -27375.58% for FY2025 (year ended Jun 30, 2025), up 222107.75 percentage points from -249483.33% in FY2024.

Analysis

Incannex Healthcare (IXHL) EBITDA Margin (2024) Analysis & Trends

  • According to Business Quant data, EBITDA Margin came in at -249483.33% in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 35.95%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 49.01%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 6.02%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 33.11%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 46.01%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -124.26%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 39.16%
10 Incannex Healthcare 32.18 Mn -252.23 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -40,650.00%
Sep 30, 2024 -8,364.86%
API Access

Incannex Healthcare EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IXHL&period=max&api_key=YOUR_API_KEY